As CREB3L1 protein levels have been reported to be downregulated via constitutive ubiquitination and proteasomal degradation in mouse embryo fibroblasts and C6 glioma cells [52], the TSA and/or DAC treatments were repeated including the proteasomal inhibitor, MG132. The gene discussed is CREB3L1; the disease is glioma.